Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - Report from OMERACT CTD-ILD working group

Journal of Rheumatology

Volumn 42, Issue 11, 2015, Pages 2168-2171

  Khanna, Dinesh ^a   Mittoo, Shikha ^b   Aggarwal, Rohit ^c   Proudman, Susanna M ^d   Dalbeth, Nicola ^e   Matteson, Eric L ^f   Brown, Kevin ^g   Flaherty, Kevin ^a   Wells, Athol U ^h   Seibold, James R ⁱ   Strand, Vibeke ^j  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f MAYO CLINIC   (United States)

^g NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^h ROYAL BROMPTON HOSPITAL   (United Kingdom)

ⁱ Scleroderma Research Consultants   (United States)

^j STANFORD UNIVERSITY   (United States)

more..

Author keywords

Interstitial lung disease; Lung diseases; Outcome assessment omeract

Indexed keywords

ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONNECTIVE TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASE; CONSENSUS; CONTROLLED STUDY; COUGHING; DISEASE COURSE; DYSPNEA; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; MEDICAL RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PSYCHOMETRY; QUALITY OF LIFE; SURVIVAL RATE; WORKSHOP; ADULT; AGED; COMORBIDITY; CONNECTIVE TISSUE DISEASES; CONSENSUS DEVELOPMENT; DISEASE MANAGEMENT; FEMALE; FOLLOW UP; INCIDENCE; LUNG DISEASES, INTERSTITIAL; MALE; MEDICAL SOCIETY; MIDDLE AGED; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

ADULT; AGED; COMORBIDITY; CONNECTIVE TISSUE DISEASES; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; SURVIVAL ANALYSIS;

EID: 84946568792     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.141182     Document Type: Article

References (13)

1. Winstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 2014;146:422-36.
2. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009;136:1397-405.
3. Bryson T, Sundaram B, Khanna D, Kazerooni EA. Connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonia: similarity and difference. Semin Ultrasound CT MR 2014;35:29-38.
4. Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010;62:2101-8.
5. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66.
6. King TE Jr., Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med 2014;189:825-31.
7. Vancheri C, du Bois RM. A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. Eur Respir J 2013;41:262-9.
8. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 2014;69:428-36.
9. Mittoo S, Frankel S, LaSage D, Strand V, Shah A, Christopher-Stine L, et al. Patient perspective: an anchor for future metric development and improved approaches to healthcare delivery in connective tissue disease related interstitial lung disease (CTD-ILD). Rheumatology 2015; Submitted.
10. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026-34.
11. Khanna D, Brown KK, Clements PJ, Elashoff R, Furst DE, Goldin J, et al. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol 2010;28:S55-62.
12. Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino MA, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol 2014;67:745-53.
13. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique-1995 update. Am J Respir Crit Care Med 1995;152:2185-98.